Experts Challenge Aspirin Guidelines Based on Their Undue Reliance on a Flawed Trial
Florida Atlantic UniversityRecent guidelines have restricted aspirin use for primary cardiovascular disease prevention, with the AHA/ACC restricting it to patients under 70 and the U.S. Preventive Services Task Force further restricting it to those under 60, even though heart attack and stroke risks increase with age. Researchers argue they were overly influenced by the flawed ASPREE trial, which failed to provide reliable evidence of aspirin鈥檚 efficacy in the enrolled age groups, and that proper statistical principles must guide trial design, analysis, and interpretation to avoid misleading conclusions.